Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI108882

Thyroid Hormonelike Actions of 3,3′,5′-l-Triiodothyronine and 3,3′-Diiodothyronine

Stathis S. Papavasiliou, Joseph A. Martial, Keith R. Latham, and John D. Baxter

Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143

Find articles by Papavasiliou, S. in: PubMed | Google Scholar

Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143

Find articles by Martial, J. in: PubMed | Google Scholar

Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143

Find articles by Latham, K. in: PubMed | Google Scholar

Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143

Find articles by Baxter, J. in: PubMed | Google Scholar

Published December 1, 1977 - More info

Published in Volume 60, Issue 6 on December 1, 1977
J Clin Invest. 1977;60(6):1230–1239. https://doi.org/10.1172/JCI108882.
© 1977 The American Society for Clinical Investigation
Published December 1, 1977 - Version history
View PDF
Abstract

l-Thyroxine is converted to 3,5,3′-l-triiodothyronine (T3) as well as to 3,3′,5′-l-triiodothyronine (reverse T3). One product of further deiodination is 3,3′-diiodothyronine (3,3′T2). The serum levels of reverse T3 and 3,3′T2 change considerably in various physiological and disease states. We previously found that reverse T3 and 3,3′T2 bind to the solubilized hepatic nuclear “receptors” for thyroid hormones. This led us to study binding and actions of these metabolites in cultured rat pituitary cells in which glucose consumption and growth hormone production are regulated by T3 and l-thyroxine.

Reverse T3 and 3,3′T2 stimulated growth hormone production and glucose consumption and inhibited nuclear binding of radioactive T3. Either metabolite produced maximal effects that equaled those of T3, and neither inhibited the T3 response. Further, additive effects were observed when reverse T3 was combined with submaximal concentrations of T3.

In serum-free and serum-containing media, concentrations of 3,3′T2 50- to 70- and 10- to 100-fold greater, respectively, than those of T3 were required for equivalent stimulations and for inhibition of nuclear binding by T3. The relative activity differences under the two conditions can be attributed to weaker serum protein binding of 3,3′T2 than T3. With cells in serum-free media, reverse T3 was a less avid competitor than 3,3′T2 for T3 binding by the nuclear receptors, and was less potent than 3,3′T2 (0.001 the potency of T3) in inducing growth hormone production or glucose oxidation. In incubations with serum-containing media, reverse T3 was an ineffective competitor for T3 binding, and had only 0.1 the inducing potency of 3,3′T2 (0.001 the potency of T3). The weaker activity of reverse T3 relative to 3,3′T2 in serum-containing media could be explained by stronger serum binding of reverse T3 than 3,3′T2. In addition, after long-term incubation of cells with radioactive reverse T3, much of the cell-associated radioactivity was recovered as 3,3′T2.

These studies suggest that reverse T3 and 3,3′T2 can stimulate thyroid hormone-regulated functions as weak agonists by acting via the same receptors that mediate T3 actions. Moreover, some of the effects of reverse T3 may be due to 3,3′T2 produced by deiodination of reverse T3.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1230
page 1230
icon of scanned page 1231
page 1231
icon of scanned page 1232
page 1232
icon of scanned page 1233
page 1233
icon of scanned page 1234
page 1234
icon of scanned page 1235
page 1235
icon of scanned page 1236
page 1236
icon of scanned page 1237
page 1237
icon of scanned page 1238
page 1238
icon of scanned page 1239
page 1239
Version history
  • Version 1 (December 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts